Genovis has a new majority owner

The company announced today that Mikael Lönn acquired 15,414,931 shares in Genovis from Farstorp Invest. The holdings represent 22% of the share capital and votes in Genovis.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.